Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV000631178 | SCV000752179 | uncertain significance | Glycogen storage disease, type IV; Glycogen storage disease IV, classic hepatic | 2022-10-05 | criteria provided, single submitter | clinical testing | This sequence change replaces leucine, which is neutral and non-polar, with proline, which is neutral and non-polar, at codon 663 of the GBE1 protein (p.Leu663Pro). This variant is present in population databases (rs761908536, gnomAD 0.01%). This variant has not been reported in the literature in individuals affected with GBE1-related conditions. ClinVar contains an entry for this variant (Variation ID: 526615). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt GBE1 protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ce |
RCV000998105 | SCV001154000 | uncertain significance | not provided | 2016-05-01 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV001563832 | SCV001786868 | uncertain significance | Glycogen storage disease, type IV | 2021-07-14 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV001563833 | SCV001786869 | uncertain significance | Adult polyglucosan body disease | 2021-07-14 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV001563832 | SCV002082372 | uncertain significance | Glycogen storage disease, type IV | 2019-10-28 | no assertion criteria provided | clinical testing |